Zokinvy

Adult Dosing .

Dosage forms:  CAP: 50 mg, 75 mg

Hutchinson-Gilford progeria syndrome

[150 mg/m^2/dose PO bid]

Start: 115 mg/m^2/dose PO bid x4mo, then 150 mg/m^2/dose PO bid; Info: round dose to nearest 25 mg increment; see pkg insert for toxicity-related dose adjustments; give with meals

processing-deficient progeroid laminopathy

[150 mg/m^2/dose PO bid]

Start: 115 mg/m^2/dose PO bid x4mo, then 150 mg/m^2/dose PO bid; Info: for patients with heterozygous LMNA mutation with progerin-like protein accumulation, or for patients with homozygous or compound heterozygous ZMPSTE24 mutation; round dose to nearest 25 mg increment; see pkg insert for toxicity-related dose adjustments; give with meals

renal dosing

[not defined]

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Dosage forms:  CAP: 50 mg, 75 mg

Hutchinson-Gilford progeria syndrome

[12 mo and older, BSA >0.39 m^2]

Dose: 150 mg/m^2/dose PO bid; Start: 115 mg/m^2/dose PO bid x4mo, then 150 mg/m^2/dose PO bid; Info: round dose to nearest 25 mg increment; see pkg insert for toxicity-related dose adjustments; give with meals

processing-deficient progeroid laminopathy

[12 mo and older, BSA >0.39 m^2]

Dose: 150 mg/m^2/dose PO bid; Start: 115 mg/m^2/dose PO bid x4mo, then 150 mg/m^2/dose PO bid; Info: for patients with heterozygous LMNA mutation with progerin-like protein accumulation, or for patients with homozygous or compound heterozygous ZMPSTE24 mutation; round dose to nearest 25 mg increment; see pkg insert for toxicity-related dose adjustments; give with meals

renal dosing

[not defined]

HD/PD: not defined

hepatic dosing

[not defined]